March 31, 2017 4:46pm

 

… Is a zero-sum game  

 

Out and about: Biostage (BSTG) leaders set the tone within and outside the company!

 

Pre-open indications:  4 hits and 2 miss                                                                   

 

I answer one question, in which company should investors put, keep and commit their money

 

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

Henry’omics:

From the pre-open’s investor’s letter title,” One way to screw-up a company’s future … utilize a false narrative or its newest moniker – “fake news”

  • Reiterating, “Referencing the title, “false narrative i.e. less than factual” has lately become the only news to emanate from Biostage (BSTG).  Press releases have been ambiguous. BSTG has made several claims in various releases that are NOT substantiated in their annual report (10-Q).”

 

Referencing the title, the rock-paper-scissors game is often used as a choosing method like a coin flip, draw straws, or throwing dice. Unlike truly random selection methods, however, rock–paper–scissors can be played by recognizing and exploiting behavior in others.

It’s the random or non-random behavior that stands out when it comes to Biostage (BSTG) – there has been and a continuous pattern of events that threaten the sustainability and viability of a publicly listed entity.

.......... And as I have written, when an organization stumbles, it is the leadership that is the root cause!

Why does a CEO NOT control the strategic and tactical execution in the company?

 

If a BOD has approved corporate proceedings, events or actions that are or could be considered suspect – shouldn’t there be a thorough investigation of the events related to actions or non-actions to eliminate ANY perception or prevent wrong doing in the future!

 

............ Threats by embedded and tempestuous dilettantes NEED to be dealt with and that goes as well to those who have aligned themselves!

It is possible to measure a company by its executive retention rate over the past two years. As I have stated … “something is rotten in the state of Denmark”!

 

However, some executives of this company exploit the weaknesses of activities to gain or retain a title advantage – learned in my early days and for many years to salute the MAN not the rank or title!

 

Cell therapy stocks traded mixed - opening down, popped to the upside and closed down.

The fact that the cell therapy sector has experienced directionless sentiment which can be laid at the feet of short term momentum affecting market cap valuation!

 

 

Pre-open indications: 4 hits and 2 miss

  • Athersys (ATHX) closed down -$0.19 – hit;
  • Biostage (BSTG) closed DOWN -$0.0008 – hit;
  • Cellectis (CLLS) closed down -$0.03 – hit;
  • Juno Therapeutics (JUNO) closed UP +0.23 – miss;
  • Spark Therapeutics (ONCE) closed down -$0.54 – miss;
  • Verastem (VSTM) closed down -$0.14 – hit;

 

 

What analytics were there today and why it was important in today’s sector outcomes?

… The DOW closed down -56.27 or -0.31% to 20,663.22 while the NASDAQ closed down -2.61 or -0.04% to 591.74 …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 12.3 following Thursday’s 11.6 after Wednesday’s 11.4 after Tuesday’s 11.5 following Monday’s 13.3

…The iShares Russell 2000 (IWM) was up +0.02% at the pre-open was and closed UP +0.16%;

… The iShares NASDAQ Biotechnology (IBB) was up +0.5% at the pre-open and closed DOWN -0.12%.

 

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The opening bell was negative with an A/DL of 19/23 and 1 flats;

·         The mid-day flipped positive with an A/DL of 21/17 and 3 flats;

·         The close was positive with an A/DL of 23/15 and 5 flats;

 

… Decliners ranged from -0.02% <CLLS> to -10% <ATHX> in 15 equities;

… Gainers ranged from +0.00% <VTGN> to +10.85% <BCLI> in 23 equities;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.